Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by investment analysts at Cowen in a research report issued on Tuesday, October 15th, AnalystRatings.com reports.
Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Saturday, October 12th. ValuEngine cut shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 4th. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a research report on Monday, August 12th. Nomura reiterated a “buy” rating and set a $37.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 13th. Finally, Morgan Stanley reduced their price objective on shares of Voyager Therapeutics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, October 11th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $27.71.
VYGR stock traded up $0.38 during trading on Tuesday, reaching $14.86. The stock had a trading volume of 263,700 shares, compared to its average volume of 451,389. The company has a market capitalization of $548.84 million, a P/E ratio of -5.40 and a beta of 2.58. The firm has a fifty day moving average price of $15.86 and a 200 day moving average price of $20.84. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $28.79.
A number of institutional investors and hedge funds have recently made changes to their positions in VYGR. Russell Investments Group Ltd. bought a new position in Voyager Therapeutics during the 3rd quarter valued at $139,000. Tocqueville Asset Management L.P. increased its position in shares of Voyager Therapeutics by 25.5% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 28,655 shares of the company’s stock valued at $493,000 after purchasing an additional 5,830 shares during the last quarter. California Public Employees Retirement System increased its position in shares of Voyager Therapeutics by 53.7% during the 3rd quarter. California Public Employees Retirement System now owns 11,728 shares of the company’s stock valued at $202,000 after purchasing an additional 4,100 shares during the last quarter. Chicago Equity Partners LLC purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $400,000. Finally, First Quadrant L P CA increased its position in shares of Voyager Therapeutics by 324.0% during the 3rd quarter. First Quadrant L P CA now owns 13,432 shares of the company’s stock valued at $231,000 after purchasing an additional 10,264 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: Net Income
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.